YT-1920 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for B-Cell Leukemia. According to GlobalData, Phase I drugs for B-Cell Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YT-1920’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YT-1920 overview
YT-1920 is under development for the treatment of relapsed and refractory B cell acute lymphocytic leukemia, B cell lymphoma, Non-Hodgkin's lymphomas including follicular lymphoma, mantle cell lymphoma. It is administered through intravenous route. The therapeutic candidate comprises of T cells genetically modified with lentivirus to express chimeric antigen receptors (CART) that act by targeting cells expressing CD19 and CD20.
It was also under development for the treatment of diffuse large B-cell lymphoma.
Bristar Immunotech Biotechnology overview
Bristar Immunotech Biotechnology (Bristar Immunotech) is a biotechnology company focused on development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T. Huaxia Yingtai is headquartered in Beijing, China.
For a complete picture of YT-1920’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
